FCR

DRUG4 trials

Sponsors

Biogen, AbbVie (prior sponsor, Abbott), French Innovative Leukemia Organisation

Conditions

Chronic Lymphocytic LeukemiaFit PatientsIntermediate Risk Chronic Lymphocytic LeukemiaRisk-Adapted and MRD-Driven Strategy

Phase 1

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

CompletedNCT00868413

AbbVie (prior sponsor, Abbott)Chronic Lymphocytic Leukemia

Start: 2009-11-30End: 2013-05-31Updated: 2013-06-07

Phase 2

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

TerminatedNCT00391066

BiogenChronic Lymphocytic Leukemia

Start: 2006-11-30End: 2010-12-31Updated: 2015-10-02

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

TerminatedNCT00801060

BiogenChronic Lymphocytic Leukemia

Start: 2008-02-29End: 2010-09-30Updated: 2015-10-02

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

CompletedNCT04010968

French Innovative Leukemia OrganisationFit Patients, Intermediate Risk Chronic Lymphocytic Leukemia, Risk-Adapted and MRD-Driven Strategy

Start: 2019-09-27End: 2025-01-30Updated: 2025-11-26

Related Papers

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

2025-12-17

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood2024-11-051 citations